Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9765MR)

This product GTTS-WQ9765MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ9765MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7195MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ11728MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ9829MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ10137MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LAG-525
GTTS-WQ12433MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ15564MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ8462MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HTI-1088
GTTS-WQ11871MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MLN-0264
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW